摘要
目的:了解我院降血糖药物以及基于胰高血糖素样肽-1(GLP-1)新型降糖药物的使用情况。方法:以计算机信息管理系统中药物的发出数量为依据,采用金额排序法和用药频度分析法,根据药物限定日剂量计算DDDs及日平均费用(DDC),并进行排序。结果:2008–2012年,我院降血糖药的销售金额持续快速增长。胰岛素及胰岛素类似物与α-葡萄糖苷酶抑制剂的销售金额相当,连续5年位居前两位,所占份额均已上升至30%以上。5年来,阿卡波糖的DDDs增长了1倍,连续处于首位。二甲双胍的DDDs从2009年的第3位上升至2012年的第2位,增长1.86倍,DDC却始终位于后3位(由6.48元降至5.84元)。结论:2008–2012年,我院降糖药的需求量逐年增加,药物种类较全面,引进了新型降糖药物。
Objective： To understand the application ofhypoglycemic drugs and the new glucagon-like peptide 1 （GLP-1） in our hospital. Methods： Analysis was based on data of the amount of delivered drugs during 2008 to 2012 documented in hospital information system. Consumption sum ranking and frequency analysis methods were performed. DDDs and defined daily cost （DDC） were calculated and ranked according to defined daily dose （DDD）. Results： The consumption sum of hypolycemic agents in our hospital increased rapidly and continuously. Consumption sum of insulins including its analogues and u-glucosidase inhibitors was similar with increasing shares to 30%, respectively, was in top two positions for five years. DDDs of acarbose increased by twice and was in the first place continuously, while DDDs of metformin （glucophage） rose to the second in 2012 from the third place in 2009 with an increasing of 1.86 times. In addition, DDC of metformin was always in the last three places and decreased from 6.48 yuan in 2008 to 5.84 yuan in 2012. GLP-1 receptor agonist exenatide was introduced into our hospital in 2012. Conclusion： Demand of hypolycemic agents increased year by year in our hospital. There were various categories of hypolycemic agents. The new type drug was available.
出处
《中国药物应用与监测》
CAS
2013年第4期218-221,共4页
Chinese Journal of Drug Application and Monitoring
